Table 1: Twelve studies selected as sitagliptin as mono therapy group (group 1).
Study |
Design |
Dose |
Control |
Follow-up |
N1 |
Baseline
HbA1c % (SE %) |
Change
of HbA1c % (SE %) |
Aschner 20062 [14] |
R, DB3 |
100 mg
QD4 |
Placebo |
24wk |
229 |
8.01
(0.88) |
-0.61
(0.064) |
Goldstein
2007 [15] |
R, DB |
100 mg
QD |
Placebo |
24wk |
175 |
8.87
(0.99) |
-0.66
(0.084) |
Hanefeld 20072 [16] |
R, DB |
100 mg
QD |
Placebo |
12wk |
106 |
7.78
(0.90) |
-0.44
(0.071) |
|
50 mg
BID |
Placebo |
108 |
7.79
(0.85) |
-0.43
(0.068) |
||
Mohan
2009 [17] |
R, DB |
100 mg
QD |
Placebo |
18wk |
339 |
8.7
(1.0) |
-0.7
(0.051) |
Nonaka 2008 [18] |
R, DB |
100 mg
QD |
Placebo |
12wk |
75 |
7.54
(0.85) |
-0.65
(0.077) |
Raz 20062 [19] |
R, DB |
100 mg
QD |
Placebo |
18wk |
193 |
8.04
(0.82) |
-0.48
(0.066) |
Scott
2007 [20] |
R, DB |
50 mg
BID |
Placebo |
12wk |
121 |
7.83
(0.95) |
-0.54
(0.071) |
Barzilai 2011 [21] |
R, DB |
100 mg
QD |
Placebo |
24wk |
101 |
7.8
(0.8) |
-0.50
(0.128) |
Iwamoto
2010 [22] |
R, DB |
50 mg
QD |
Voglibose |
12wk |
155 |
7.7
(0.9) |
-0.70
(0.051) |
Aschner 2010 [23] |
R, DB |
100 mg
QD |
Metformin |
24wk |
455 |
7.2
(0.7) |
-0.43
(0.051) |
Perez-Monteverde 2011 [24] |
R, DB |
100 mg
QD |
Pioglitazone |
12wk |
231 |
9.0
(1.4) |
-1.00
(0.077) |
Chan
20082 [25] |
R, DB |
100 mg
QD |
Placebo/Glipizide |
12wk |
55 |
7.6
(0.9) |
-0.60
(0.102) |
1N: number of patients available for computing change of
HbA1c if reported, and number of randomized patients otherwise.
2Studies have different dose groups of Sitagliptin.
If there is a group of 100mg (once per day), we used data for this group; and
used data for the group with maximum dose otherwise. For Hanefeld
et al. (2007), we kept two groups (100mg once per day or 50mg twice per day).
Chan 2008 have multiple follow-up visits, and we used the visit closest to 24
weeks.
3R: randomized; DB: double-blinded
4QD: once a day; BID: twice a day